BioNTech raises US$250m from investors including Temasek
[FRANKFURT] BioNTech said Singapore's investment company Temasek and other investors are injecting US$250 million into the German biotech firm through a private placement.
The company, which is developing a Covid-19 vaccine, said the transaction includes the purchase of about US$139 million in ordinary shares and a US$112 million investment in four-year mandatory convertible notes.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Once staunchly pro-China, Malaysian Chinese businesses are now distancing themselves from Beijing
Stocks to watch: HPL, Aims Apac Reit, Zico, Advanced Systems Automation, ComfortDelGro
‘How many will survive?’: Bubble fears arise as China’s humanoid robotics face reality check
Smaller board lots can’t fix a market run by three banks